Hook & thesis
The market is waking up to a clear narrative: large drugmakers are in early-stage talks to carve out Inhibrx's oncology assets, and that chatter is carrying real dollar signs. Headlines on 04/22/2026 linking interest from major pharmas and a potential joint spin-off valuing the combined oncology assets north of $8-$9 billion sent shares into a parabolic intraday rally and left a classic momentum-following trade on the table.
My base trade idea: buyers should look to participate on a pullback to the rally’s consolidation zone and ride momentum into an initial upside target at $160, using a disciplined stop to limit downside. This is a directional, event-driven swing trade, not a buy-and-hold thesis on the company’s entire pipeline.
What the company does and why the market cares
Inhibrx is a clinical-stage biopharma focused on modular protein engineering and multivalent biologic candidates. The clinical pipeline centers on multivalent agonists such as INBRX-109 and INBRX-106, the latter being tested as both a standalone therapy and in combination with Merck's Keytruda. If a carve-out or spin-off transaction proceeds, the market would be pricing a discrete oncology franchise separately from the remainder of the company, potentially unlocking value much faster than waiting for long clinical readouts.
Why this move matters right now
- Headline-driven re-rating: 04/22/2026 reports put a multi-billion dollar valuation on the oncology assets, a valuation that dwarfs Inhibrx’s current market cap and creates a clear catalyst for a re-rate.
- Low float, high short interest: The company’s public float is approximately 10.24 million shares with short interest above 2.1 million shares as of the latest settlement. That dynamic amplifies moves on positive news and can steepen rallies during squeezes.
- Momentum technicals: The 9-day EMA ($87.45) and MACD indicate bullish momentum while the 52-week range (low $10.84, high $155.29) shows how quickly sentiment has shifted.
Key fundamental snapshots to keep in mind
| Metric | Value |
|---|---|
| Market cap | $1,718,290,622 |
| Shares outstanding | 14,906,659 |
| Float | 10,241,095 |
| 52-week range | $10.84 - $155.29 |
| EPS (trailing) | -$9.59 |
| Free cash flow (most recent) | -$129,825,000 |
| Enterprise value | $1,204,498,587 |
Valuation framing
On a headline basis the shares still look cheap relative to the rumored asset valuation if a spin-off or asset sale were to materialize at multi-billion dollar levels. Current market cap is about $1.72 billion, while press speculation points to combined oncology asset valuations well above $8 billion. That gap explains the magnitude of the move and why the market is trying to re-price the equity rapidly.
That said, the company’s headline multiples are extreme and reflect its clinical-stage profile: trailing EPS is deeply negative at -$9.59, price-to-book and price-to-sales metrics are not meaningful in the traditional sense. The valuation improvement implied by a spin-off would rely on buyers paying a premium for discrete, nearer-term oncology value as opposed to the whole-company risk of long clinical development timelines.
Technical context
The stock ripped to an intraday high of $155.29 on 04/22/2026 before settling back near $118. Momentum indicators are bullish (MACD histogram positive, EMA ribbons sloping up), but the RSI sits elevated (~79), signaling an overbought condition that often precedes short-term consolidation. Average daily volume has expanded dramatically relative to recent norms, and short-volume metrics show heavy short participation — a classic setup for amplified moves on news.
Catalysts to watch (near-term)
- Any official announcement of a formal spin-off process or deal term sheet from Inhibrx or potential partners - would be a direct re-rating event.
- Regulatory or clinical readouts on INBRX-106 that confirm the asset’s standalone potential or favorable combo data with Keytruda.
- Counterparty confirmations or filings showing engagement from major pharmas - even partial confirmations can keep momentum alive.
- Unwinding of short positions if volatility remains elevated; look for short-interest updates in the coming settlement cycles.
Trade plan - actionable
Trade stance: Long on a momentum consolidation pullback.
- Entry: Buy at $118.00.
- Stop loss: $95.00.
- Target: $160.00 (primary). If the spin-off is announced and momentum extends, consider a secondary upside target around $200 for position-splitting tactics.
- Horizon: mid term (45 trading days) - expect the trade to resolve within the next several weeks as spin-off discussions either firm up or the headline fades and volatility cools.
Why these levels? $118 is near the recent pullback level after the intraday spike and gives upside back toward the intraday high while offering a defined risk band. The $95 stop keeps loss under control should the rally collapse and the market reassert fundamentals over rumors. $160 is modestly above the intraday high and captures continuation of the momentum re-rate if bidders and process transparency accelerate.
Position sizing & risk management
This is a high-risk biotech momentum trade. Limit any single-trade exposure to a small percentage of liquid capital (for most retail accounts, 1-2% of portfolio value). Use the stop; if volatility spikes and the stop is taken on heavy volume, step aside and avoid averaging down into a squeeze-driven top.
Risks and counterarguments
- Execution risk on headlines - early-stage discussions do not guarantee a deal. If buy-side interest evaporates or talks stall, the stock can retrace sharply.
- Clinical and fundamental risk - the company is still clinical-stage with negative EPS and significant cash burn (free cash flow was negative $129.8 million). Absent a transaction, long-term value depends on clinical outcomes.
- High short interest and crowded positioning - while this can amplify upside, it can also amplify downside if sentiment shifts and shorts hold through the news.
- Technical risk - the RSI is overbought and the stock already printed a 52-week high intraday; pullbacks to test the move are normal and can be swift.
- Counterargument - the rally is purely speculative and detached from fundamentals. If the market decides the spin-off chatter was overblown, the multiple that’s been bid into the stock could contract quickly, sending shares back toward levels justified by cash runway and long-term trial risk.
What would change my mind
I would abandon this momentum trade and flip bearish if any of the following occur: a clear public statement that talks have ended or there will be no spin-off, a disappointing clinical update that undermines the strategic value of INBRX-106, or a washout through the $95 stop on high volume. Conversely, a signed letter of intent, public confirmation from a credible pharma partner, or formal process launch would make me more bullish and likely extend targets toward $200 or higher.
Conclusion
Inhibrx’s move on 04/22/2026 is a classic headline-driven biotech trade: small float, significant short interest, and a concrete potential corporate action that could materially change valuation. For traders comfortable with biotech volatility, buying a disciplined pullback to $118 with a $95 stop and an initial target of $160 offers a reasonable risk/reward profile for a mid-term (45 trading days) swing. Keep position sizes small, follow news flow closely, and be prepared to tighten stops or take profits quickly if the story confirms or collapses.
Trade is event-driven and time-sensitive. Manage allocation and exits tightly; this is a trade, not a long-term investment recommendation.